Transurethral resection vs microwave thermotherapy of the prostate: A cost-consequences analysis

BJU International

Volumn 92, Issue 7, 2003, Pages 713-718

  De La Rosette, J J M C H ^a   Floratos, D L ^b   Severens, J L ^b   Kiemeney, L A L M ^b   Debruyne, F M J ^b   Laguna, M Pilar ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Benign prostatic hyperplasia; Consequences; Cost; Hyperthermia; Prostatic resection

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERTHERMIC THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; SURVIVAL; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URETHRA DISEASE; URINE FLOW RATE; URODYNAMICS; UROFLOWMETRY;

AGED; AMBULATORY CARE; COST-BENEFIT ANALYSIS; DAY CARE; FOLLOW-UP STUDIES; HEALTH RESOURCES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MICROWAVES; NETHERLANDS; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; RETREATMENT; RISK FACTORS; SURVIVAL ANALYSIS; TRANSURETHRAL RESECTION OF PROSTATE; UROLOGIC DISEASES;

EID: 0344395148     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04470.x     Document Type: Article

References (30)

1. Lunenfeld B. Aging male. The Aging Male 1998; 1: 7
2. United Nations Department for Economic and Social Information and Policy Analysis Population Division. World Population Prospects: the 1994 Revision. Doc ST/ESA/SER/a/145. New York: United Nations, 1994
3. Diokno AC, Brown MB, Goldstein N, Herzog AR. Epidemiology of bladder emptying symptoms in elderly men. J Urol 1992; 148: 1817-21
4. Napalkov P, Maisonneuve P, Boyle P. Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology 1995; 46 (3 Suppl. A): 41-6
5. Lepor H, Rigaud G. The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J Urol 1990; 143: 533-7
6. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy. Immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; 141: 243-7
7. Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP. Immediate and postoperative complications of transurethral prostatectomy in the 1990s. J Urol 1999; 162: 1307-10
8. Jorgensen JB, Seidelin C, Petersen F, Frimodt-Moller C. Does old age contraindicate TURP. Eur Urol 1997; 31: 281-5
9. Roos NP, Wennberg JE, Malenka DJ et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 1989; 320: 1120-4
10. Lu YG, Barry MJ, Chang CH, Wasson JH, Wennberg JE. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate and Patient Outcomes Research Team (PORT). Urology 1994; 44: 692-8
11. McConnell JD, Barry MJ, Bruskewitz RC et al. Benign Prostatic Hyperplasia. Diagnosis and treatment. Clinical Practice Guideline. Number 8. Agency for Health Care Policy and Research. AHCPR Publication no. 94-0582. Rockville MD: Public Health Service, US Department of Health and Human Services, 1994: 2-94
12. Elixhauser A, Steiner CA. Most Common Diagnoses and Procedures in US Community Hospitals. HCUP Research Note. Agency for Health Care Policy and Research, Rockville, MD. Table 2: most common diagnoses - D.78, Hyperplasia of the prostate. URL, http://www.ahcpr.gov/ data/hcup/commdx/table1d.htm #39, 1996
13. de la Rosette JJMCH, D'Ancona FC, Debruyne FM. Current status of thermotherapy of the prostate. J Urol 1997; 157: 430-8
14. Thalmann GN, Graber SF, Bitton A, Burkhard FC, Gruenig O, Studer UE. Transurethral thermotherapy for benign prostatic hyperplasia significantly decreases infravesical obstruction: results in 134 patients after 1 year. J Urol 1999; 162: 387-93
15. Floratos DL, Sonke GS, Francisca EA et al. High energy transurethral microwave thermotherapy for the treatment of patients in urinary retention. J Urol 2000; 163: 1457-60
16. Francisca EA, d'Ancona FC, Debruyne FM, de la Rosette JJMCH. High-energy transurethral microwave thermotherapy (TUMT 2.5) in the treatment of BPH. Results of a prospective study with 4-yearsfollow-up. Eur Urol 1999; 35 (Suppl. 2): 52, A208
17. Floratos DL, Kiemeney LALM, Rossi C, Kortmann BBM, Debruyne FMJ, de la Rosette JJMCH. Long-term followup of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 2001; 165: 1533-8
18. Statistics Netherlands. (Centraal Bureau voor de Statistiek, CBS). (1997b). Annual statistics [in Dutch]. Voorburg/Heerlen: CBS 1997
19. Ellerbeck E. Health care costs as percent of Gross Domestic Product. http:// www2.kumc.edu/instruction/medicine/ pmed960/calendar.htm 1999
20. Drummond, MF, O'Brien, B, Stoddart, GL, Torrance, GW. eds. Basic types of economic evaluation. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. New York: Oxford University Press Inc., 1997: 6-26
21. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1172-7
22. Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics 1998; 13: 277-88
23. Baxter K, Coast J, Donovan J. A guide to undertaking economic evaluations within randomized controlled trials of treatments for lower urinary tract symptoms. BJU Int 2000; 85: 36-41
24. Lowe FC, McDaniel RL, Chmiel JJ, Hillman AL. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 1995; 46: 477-83
25. Chirikos TN, Sanford E. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 1996; 155: 1311-6
26. Keoghane SR, Lawrence KC, Gray AM et al. A double-blind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow-up. BJU Int 2000; 85: 74-8
27. Jepsen JV, Bruskewitz RC. Economics of transurethral thermotherapy of the prostate. World J Urol 1998; 16: 138-41
28. Baltussen RMPM, Wielink G, Stoevelaar HJ, Van der Wilt GJ, Severens JL, Ament AJHA. The economic impact of introducing transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia: a scenario analysis. World J Urol 1998; 16: 142-7
29. Blute M, Ackerman SJ, Rein AL et al. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II - results. Urology 2000; 56: 981-7
30. Fayers PM, Hand DJ. Generalisaton from phase III clinical trials, survival, quality of life, and health economics. Lancet 1997; 350: 1025-7